Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab

Table 2 Diameter and maximum standardized uptake value (SUVmax) of each lesion at each timepoint in treatment with nivolumab

Patient	Site of Lesion	Baseline		1st assessment			2nd assessment
Patient	Site of Lesion	Diameter (mm)	SUVmax	Diameter (mm)	SUVmax	Response	Diameter (mm)	Response
1	kidney (primary)	63	7.5	65	3.7	SD	62	SD
	LN	60	7.6	61	6.3		60
	lung	10	1.5	10	1.6		7
2	bone	49	5.4	50	5.0	SD	54	PD^a
	lung	27	3.5	29	3.3		33
	lung	12	2.8	14	2.2		14
3	lung	39	8.8	28	8.5	SD	18	PR
3	subcutaneous	13	1.9	10	1.0		4
4	bone	65	5.9	57	4.7	SD	60	SD
	adrenal	45	3.7	45	3.6		60
	bone	41	3.4	38	3.3		35
5	subcutaneous	161	5.1	151	6.7	SD	90	PR
	adrenal	38	5.1	39	6.3		21
	liver	33	4.5	38	5.4		23
	LN	15	3.4	12	3.4		0
	lung	12	5	12	5.4		12
	muscle	45	4.2	45	5.6		31
	bone	15	2.8	14	3.5		0
	subcutaneous	15	2.1	14	3.7		0
6	lung	18	4.1	19	2.0	SD	8	PR
	lung	23	3.5	20	6.3		11
	adrenal	28	2.5	28	5.1		21
7	LN	15	3.3	15	2.9	SD	6	PR
7	lung	36	4.8	36	4.2		17
8	lung	22	5.1	17	6.1	SD	10	SD
	lung	17	2.2	14	3.0		5
	adrenal	32	3.7	34	2.8		41
9	lung	42	4.0	34	3.4	SD	13	PR
	LN	16	4.8	10	3.0		8
	LN	15	3.4	15	3.2		15

ISSN: 1471-2407